Discover CTSim™
Accelerate Drug Discovery With Quantum Intelligence
Accelerate Drug Discovery With Quantum Intelligence
Accelerate Drug Discovery With Quantum Intelligence
Accelerate Drug Discovery With Quantum Intelligence
CTSim™ leverages quantum computing algorithms to revolutionize early-stage drug development by exploring billions of molecular combinations simultaneously
CTSim™
From molecular design to optimized leads in months, not years
CTSim™
From molecular design to optimized leads in months, not years
CTSim™
From molecular design to optimized leads in months, not years
CTSim™
From molecular design to optimized leads in months, not years
The Challenge
The Drug Discovery Crisis
The Drug
Discovery Crisis
Traditional methods cost billions and take decades
Limited Chemical Coverage
Manual screening examines a tiny fraction of molecules, leaving breakthrough therapies undiscovered.
Limited Chemical Coverage
Manual screening examines a tiny fraction of molecules, leaving breakthrough therapies undiscovered.
Limited Chemical Coverage
Manual screening examines a tiny fraction of molecules, leaving breakthrough therapies undiscovered.
Limited Chemical Coverage
Manual screening examines a tiny fraction of molecules, leaving breakthrough therapies undiscovered.
Poor Prediction Accuracy
Current models achieve 60-70% accuracy in drug-target binding, causing high clinical trial failure rates.
Poor Prediction Accuracy
Current models achieve 60-70% accuracy in drug-target binding, causing high clinical trial failure rates.
Poor Prediction Accuracy
Current models achieve 60-70% accuracy in drug-target binding, causing high clinical trial failure rates.
Current models achieve 60-70% accuracy in drug-target binding, causing high clinical trial failure rates.
Unsustainable Costs
Drug discovery costs $2.6B per approved drug with 90% failure rates, making rare diseases financially unviable.
Unsustainable Costs
Drug discovery costs $2.6B per approved drug with 90% failure rates, making rare diseases financially unviable.
Unsustainable Costs
Drug discovery costs $2.6B per approved drug with 90% failure rates, making rare diseases financially unviable.
Unsustainable Costs
Drug discovery costs $2.6B per approved drug with 90% failure rates, making rare diseases financially unviable.
Limited Optimization
Conventional methods require years of iterative testing to optimize compounds for efficacy and safety.
Limited Optimization
Conventional methods require years of iterative testing to optimize compounds for efficacy and safety.
Limited Optimization
Conventional methods require years of iterative testing to optimize compounds for efficacy and safety.
Limited Optimization
Conventional methods require years of iterative testing to optimize compounds for efficacy and safety.
Our Solution
Quantum-Powered Drug Design
Revolutionary capabilities that transform molecular discovery
Quantum Molecular Exploration
Explore billions of molecular combinations simultaneously using quantum algorithms that exceed classical computational limits.
Quantum Molecular Exploration
Explore billions of molecular combinations simultaneously using quantum algorithms that exceed classical computational limits.
Quantum Molecular Exploration
Explore billions of molecular combinations simultaneously using quantum algorithms that exceed classical computational limits.
Quantum Molecular Exploration
Explore billions of molecular combinations simultaneously using quantum algorithms that exceed classical computational limits.
>90% Prediction Accuracy
Achieve >90% drug-target binding accuracy compared to 60-70% with traditional methods, improving success rates.
>90% Prediction Accuracy
Achieve >90% drug-target binding accuracy compared to 60-70% with traditional methods, improving success rates.
>90% Prediction Accuracy
Achieve >90% drug-target binding accuracy compared to 60-70% with traditional methods, improving success rates.
>90% Prediction Accuracy
Achieve >90% drug-target binding accuracy compared to 60-70% with traditional methods, improving success rates.
AI Lead Optimization
Automatically refine molecular structures for enhanced efficacy, selectivity, and reduced toxicity using machine learning.
AI Lead Optimization
Automatically refine molecular structures for enhanced efficacy, selectivity, and reduced toxicity using machine learning.
AI Lead Optimization
Automatically refine molecular structures for enhanced efficacy, selectivity, and reduced toxicity using machine learning.
AI Lead Optimization
Automatically refine molecular structures for enhanced efficacy, selectivity, and reduced toxicity using machine learning.
Pre-Synthesis Safety Screening
Identify safety concerns before synthesis, eliminating problematic candidates early and reducing development costs.
Pre-Synthesis Safety Screening
Identify safety concerns before synthesis, eliminating problematic candidates early and reducing development costs.
Pre-Synthesis Safety Screening
Identify safety concerns before synthesis, eliminating problematic candidates early and reducing development costs.
Pre-Synthesis Safety Screening
Identify safety concerns before synthesis, eliminating problematic candidates early and reducing development costs.
Platform Capabilities
Enterprise-Grade Platform
Enterprise-Grade Platform
Enterprise-Grade Platform
Enterprise-Grade Platform
CTSim™ offers Comprehensive capabilities for pharmaceutical development
QuantumVision™ v3.0 offers a comprehensive suite of tools for modern clinical imaging workflows, driving efficiency and better patient care.
QuantumVision™ v3.0 offers a comprehensive suite of tools for modern clinical imaging workflows, driving efficiency and better patient care.
CTSim™ Simulation Engine
Simulate molecular interactions at atomic precision to accurately predict binding affinities, conformational changes, and reaction mechanisms.
CTSim™ Simulation Engine
Simulate molecular interactions at atomic precision to accurately predict binding affinities, conformational changes, and reaction mechanisms.
CTSim™ Simulation Engine
Simulate molecular interactions at atomic precision to accurately predict binding affinities, conformational changes, and reaction mechanisms.
CTSim™ Simulation Engine
Simulate molecular interactions at atomic precision to accurately predict binding affinities, conformational changes, and reaction mechanisms.
ADMET Prediction
Predict absorption, distribution, metabolism, excretion, and toxicity properties before synthesis, eliminating poor pharmacokinetic candidates.
ADMET Prediction
Predict absorption, distribution, metabolism, excretion, and toxicity properties before synthesis, eliminating poor pharmacokinetic candidates.
ADMET Prediction
Predict absorption, distribution, metabolism, excretion, and toxicity properties before synthesis, eliminating poor pharmacokinetic candidates.
ADMET Prediction
Predict absorption, distribution, metabolism, excretion, and toxicity properties before synthesis, eliminating poor pharmacokinetic candidates.
Multi-Target Design
Optimize molecules for multiple therapeutic targets simultaneously, enabling superior polypharmacology drugs with enhanced efficacy.
Multi-Target Design
Optimize molecules for multiple therapeutic targets simultaneously, enabling superior polypharmacology drugs with enhanced efficacy.
Multi-Target Design
Optimize molecules for multiple therapeutic targets simultaneously, enabling superior polypharmacology drugs with enhanced efficacy.
Multi-Target Design
Optimize molecules for multiple therapeutic targets simultaneously, enabling superior polypharmacology drugs with enhanced efficacy.
Patent Intelligence
Automated patent landscape analysis and freedom-to-operate assessments ensure novel designs avoid existing intellectual property claims.
Patent Intelligence
Automated patent landscape analysis and freedom-to-operate assessments ensure novel designs avoid existing intellectual property claims.
Patent Intelligence
Automated patent landscape analysis and freedom-to-operate assessments ensure novel designs avoid existing intellectual property claims.
Patent Intelligence
Automated patent landscape analysis and freedom-to-operate assessments ensure novel designs avoid existing intellectual property claims.
Collaborative Workflows
Cloud-based platform enables collaboration between computational chemists, medicinal chemists, and pharmacologists throughout discovery.
Collaborative Workflows
Cloud-based platform enables collaboration between computational chemists, medicinal chemists, and pharmacologists throughout discovery.
Collaborative Workflows
Cloud-based platform enables collaboration between computational chemists, medicinal chemists, and pharmacologists throughout discovery.
Collaborative Workflows
Cloud-based platform enables collaboration between computational chemists, medicinal chemists, and pharmacologists throughout discovery.
API Integration
RESTful APIs integrate with laboratory information systems, electronic lab notebooks, and compound management platforms.
API Integration
RESTful APIs integrate with laboratory information systems, electronic lab notebooks, and compound management platforms.
API Integration
RESTful APIs integrate with laboratory information systems, electronic lab notebooks, and compound management platforms.
API Integration
RESTful APIs integrate with laboratory information systems, electronic lab notebooks, and compound management platforms.
Technology
Proprietary Technology Stack
Built on cutting-edge AI research with robust, secure, and scalable clinical-grade infrastructure.
Python Ecosystem
Python Ecosystem
Python Ecosystem
Python Ecosystem
TensorFlow/PyTorch
TensorFlow/PyTorch
TensorFlow/PyTorch
TensorFlow/PyTorch
Advanced CNNs
Advanced CNNs
Advanced CNNs
Advanced CNNs
HIPAA Compliant
HIPAA Compliant
HIPAA Compliant
HIPAA Compliant
Cloud Native
Cloud Native
Cloud Native
Cloud Native
Multi-Platform
Multi-Platform
Multi-Platform
Multi-Platform
Our Difference
CTSim™ vs the world
Quantumvision™
vs the world
Quantumvision™
vs the world
CTSim™ vs the world
Built on cutting-edge AI research with robust, secure, and scalable clinical-grade infrastructure.
Built on cutting-edge AI research with robust, secure,
and scalable clinical-grade infrastructure.
Built on cutting-edge AI research with robust, secure,
and scalable clinical-grade infrastructure.
Built on cutting-edge AI research with robust, secure, and scalable clinical-grade infrastructure.
Current Methods
Current Methods
Current Methods
CTSim™
Chemical Space Exploration
Molecular combination screening
Limited subset manual screening
Billions of compounds analyzedutes
Molecular Interaction Prediction
Drug-target binding accuracy
Classical models (60-70% accuracy)
Quantum-precise modeling (>90%)
Lead Optimization
Compound refinement for efficacy
Iterative manual testing
AI-driven automated optimization
Early Liability Detection
Adverse effect prediction
Late-stage discovery
Pre-synthesis prediction
Development Timeline
Early-stage discovery to lead
10-15 years
Months for lead candidates
Development Cost
Early-stage R&D investment
$2.6B per drug
60-70% cost reduction
Clinical Trial Success Rate
Candidate progression probability
<12%
Projected 25-30% improvement
Synthesis Route Planning
Manufacturing pathway efficiency
Manual design
Quantum-optimized routes
Discovery Throughput
Novel candidate identification rate
Dozens per year
Hundreds per month
Our people
Leadership Team
Combining decades of experience in AI, medical imaging, clinical practice, and healthcare business development, our leadership drives innovation from quantum research to patient impact.
T. Ritchie
Chief Executive Officer
Managing a multi-billion dollar investment fund, 25+ years in business development and leadership.
T. Ritchie
Chief Executive Officer
Managing a multi-billion dollar investment fund, 25+ years in business development and leadership.
T. Ritchie
Chief Executive Officer
Managing a multi-billion dollar investment fund, 25+ years in business development and leadership.
T. Ritchie
Chief Executive Officer
Managing a multi-billion dollar investment fund, 25+ years in business development and leadership.
Dr. Alex F. Metwaly
Co-Founder & Chief Scientific Officer
20+ years in BioTech and AI, Former Chair of National Data Center, 150+ publications in deep learning.
Dr. Alex F. Metwaly
Co-Founder & Chief Scientific Officer
20+ years in BioTech and AI, Former Chair of National Data Center, 150+ publications in deep learning.
Dr. Alex F. Metwaly
Co-Founder & Chief Scientific Officer
20+ years in BioTech and AI, Former Chair of National Data Center, 150+ publications in deep learning.
Dr. Alex F. Metwaly
Co-Founder & Chief Scientific Officer
20+ years in BioTech and AI, Former Chair of National Data Center, 150+ publications in deep learning.
Dr. F. A. Naftolin
Chief Medical Officer
MD, PhD in Women's Health, Expert in drug design, clinical trials, and healthcare strategy.
Dr. F. A. Naftolin
Chief Medical Officer
MD, PhD in Women's Health, Expert in drug design, clinical trials, and healthcare strategy.
Dr. F. A. Naftolin
Chief Medical Officer
MD, PhD in Women's Health, Expert in drug design, clinical trials, and healthcare strategy.
Dr. F. A. Naftolin
Chief Medical Officer
MD, PhD in Women's Health, Expert in drug design, clinical trials, and healthcare strategy.
P. Wolfe
Board Head
Managing Partner at top-tier VC firm, 30+ years in strategic technology investments and growth scaling.
P. Wolfe
Board Head
Managing Partner at top-tier VC firm, 30+ years in strategic technology investments and growth scaling.
P. Wolfe
Board Head
Managing Partner at top-tier VC firm, 30+ years in strategic technology investments and growth scaling.
P. Wolfe
Board Head
Managing Partner at top-tier VC firm, 30+ years in strategic technology investments and growth scaling.
James Wilson
Head of Business Development
Former VP at Siemens Healthineers, 20+ years in medical device commercialization and global sales.
James Wilson
Head of Business Development
Former VP at Siemens Healthineers, 20+ years in medical device commercialization and global sales.
James Wilson
Head of Business Development
Former VP at Siemens Healthineers, 20+ years in medical device commercialization and global sales.
James Wilson
Head of Business Development
Former VP at Siemens Healthineers, 20+ years in medical device commercialization and global sales.
TBN
Head of Sales (Recruiting)
Candidate search underway for experienced sales leader with deep hospital and health system network.
TBN
Head of Sales (Recruiting)
Candidate search underway for experienced sales leader with deep hospital and health system network.
TBN
Head of Sales (Recruiting)
Candidate search underway for experienced sales leader with deep hospital and health system network.
TBN
Head of Sales (Recruiting)
Candidate search underway for experienced sales leader with deep hospital and health system network.
Confidential Material
This section contains proprietary information intended for potential investors.
Confidential Material
This section contains proprietary information intended for potential investors.
Confidential Material
This section contains proprietary information intended for potential investors.
Confidential Material
This section contains proprietary information intended for potential investors.
Our people
Leadership Team
Combining decades of experience in AI, medical imaging, clinical practice, and healthcare business development, our leadership drives innovation from quantum research to patient impact.
Our people
Leadership Team
Combining decades of experience in AI, medical imaging, clinical practice, and healthcare business development, our leadership drives innovation from quantum research to patient impact.
Market Opportunity
Massive Market Opportunity
Massive
Market Opportunity
Massive
Market Opportunity
Massive Market Opportunity
Born from the collective ambition of industry veterans and technology innovators, our mission is to expedite the journey of groundbreaking healthcare solutions from conception to global markets.
$4.5B
Global AI Medical Imaging Market (2023)
$4.5B
Global AI Medical Imaging Market (2023)
$4.5B
Global AI Medical Imaging Market (2023)
$4.5B
Global AI Medical Imaging Market (2023)
$45B
Projected Market by 2030 (35% CAGR)
$45B
Projected Market by 2030 (35% CAGR)
$45B
Projected Market by 2030 (35% CAGR)
$45B
Projected Market by 2030 (35% CAGR)
8,000+
Hospitals in US & EU Target Market
8,000+
Hospitals in US & EU Target Market
8,000+
Hospitals in US & EU Target Market
8,000+
Hospitals in US & EU Target Market
$2.5M
Avg. Hospital Imaging Budget (Annual)
$2.5M
Avg. Hospital Imaging Budget (Annual)
$2.5M
Avg. Hospital Imaging Budget (Annual)
$2.5M
Avg. Hospital Imaging Budget (Annual)
Confidential Material
This section contains proprietary information intended for potential investors.
Confidential Material
This section contains proprietary information intended for potential investors.
Confidential Material
This section contains proprietary information intended for potential investors.
Confidential Material
This section contains proprietary information intended for potential investors.
Technology
Proprietary Technology Stack
Built on cutting-edge AI research with robust, secure, and scalable clinical-grade infrastructure.
$
3M
Innovate
Securing capital for product refinement, critical clinical validation studies, and initial strategic market entry.
FDA clearance preparation & filing
Pilot deployments at 5 major hospital systems
Team expansion to 15 full-time members
Clinical validation studies completion
$
3M
Innovate
Securing capital for product refinement, critical clinical validation studies, and initial strategic market entry.
FDA clearance preparation & filing
Pilot deployments at 5 major hospital systems
Team expansion to 15 full-time members
Clinical validation studies completion
$
3M
Innovate
Securing capital for product refinement, critical clinical validation studies, and initial strategic market entry.
FDA clearance preparation & filing
Pilot deployments at 5 major hospital systems
Team expansion to 15 full-time members
Clinical validation studies completion
$
3M
Innovate
Securing capital for product refinement, critical clinical validation studies, and initial strategic market entry.
FDA clearance preparation & filing
Pilot deployments at 5 major hospital systems
Team expansion to 15 full-time members
Clinical validation studies completion
$
10M
Series A (Projected)
Targeted capital for full commercial scaling, regulatory approvals, and platform module expansion.
EU MDR & full FDA 510(k) clearance
Expansion to 50+ hospital systems globally
Development of 3 new specialty AI modules
International market penetration
$
10M
Series A (Projected)
Targeted capital for full commercial scaling, regulatory approvals, and platform module expansion.
EU MDR & full FDA 510(k) clearance
Expansion to 50+ hospital systems globally
Development of 3 new specialty AI modules
International market penetration
$
10M
Series A (Projected)
Targeted capital for full commercial scaling, regulatory approvals, and platform module expansion.
EU MDR & full FDA 510(k) clearance
Expansion to 50+ hospital systems globally
Development of 3 new specialty AI modules
International market penetration
$
10M
Series A (Projected)
Targeted capital for full commercial scaling, regulatory approvals, and platform module expansion.
EU MDR & full FDA 510(k) clearance
Expansion to 50+ hospital systems globally
Development of 3 new specialty AI modules
International market penetration
Ready to See the Full Picture?
This section contains proprietary information intended for potential investors.
Ready to See the Full Picture?
This section contains proprietary information intended for potential investors.
Ready to See the Full Picture?
This section contains proprietary information intended for potential investors.
Ready to See the Full Picture?
This section contains proprietary information intended for potential investors.